HomeCompareFMBIO vs JNJ

FMBIO vs JNJ: Dividend Comparison 2026

FMBIO yields 10.98% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FMBIO wins by $21.73M in total portfolio value
10 years
FMBIO
FMBIO
● Live price
10.98%
Share price
$26.45
Annual div
$2.91
5Y div CAGR
53%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.76M
Annual income
$17,342,271.90
Full FMBIO calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — FMBIO vs JNJ

📍 FMBIO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFMBIOJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FMBIO + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FMBIO pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FMBIO
Annual income on $10K today (after 15% tax)
$933.55/yr
After 10yr DRIP, annual income (after tax)
$14,740,931.11/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, FMBIO beats the other by $14,736,945.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FMBIO + JNJ for your $10,000?

FMBIO: 50%JNJ: 50%
100% JNJ50/50100% FMBIO
Portfolio after 10yr
$10.90M
Annual income
$8,673,480.65/yr
Blended yield
79.60%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

FMBIO
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FMBIO buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFMBIOJNJ
Forward yield10.98%2.13%
Annual dividend / share$2.91$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR53%28%
Portfolio after 10y$21.76M$30.3K
Annual income after 10y$17,342,271.90$4,689.40
Total dividends collected$21.35M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FMBIO vs JNJ ($10,000, DRIP)

YearFMBIO PortfolioFMBIO Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$12,380$1,680.40$10,592$272.30+$1.8KFMBIO
2$16,222$2,974.77$11,289$357.73+$4.9KFMBIO
3$22,931$5,573.48$12,123$472.89+$10.8KFMBIO
4$35,802$11,265.59$13,141$629.86+$22.7KFMBIO
5$63,458$25,150.37$14,408$846.81+$49.0KFMBIO
6$131,644$63,743.63$16,021$1,151.60+$115.6KFMBIO
7$329,944$189,085.38$18,122$1,588.22+$311.8KFMBIO
8$1,030,691$677,650.73$20,930$2,228.20+$1.01MFMBIO
9$4,129,764$3,026,924.53$24,792$3,191.91+$4.10MFMBIO
10$21,761,119$17,342,271.90$30,274$4,689.40+$21.73MFMBIO

FMBIO vs JNJ: Complete Analysis 2026

FMBIOStock

First Midwest Bancorp, Inc. operates as the bank holding company for First Midwest Bank that provides various banking products and services. The company accepts checking, NOW, money market, and savings accounts, as well as various types of short-term and long-term certificates of deposit. Its loan products include working capital needs; accounts receivable financing; inventory and equipment financing; sector-based lending, including healthcare, asset-based lending, structured finance, and syndications; agricultural loans; and mortgages, home equity lines and loans, personal loans, specialty loans, and consumer secured and unsecured loans, as well as funding for the construction, purchase, refinance, or improvement of commercial real estate properties. In addition, the company offers treasury management products and services comprising automated clearing house collection, lockbox, remote deposit capture, and financial electronic data interchange; wire transfer, account reconciliation, controlled disbursement, direct deposit, and positive pay services; information reporting services; corporate credit cards; and liquidity management, fraud prevention, and merchant services. Further, it provides fiduciary and executor, financial planning, investment advisory, employee benefit plan, and private banking services to corporate and public retirement plans, foundations and endowments, high net worth individuals, and multi-employer trust funds. Additionally, the company offers debit and automated teller machine (ATM), and credit cards; internet and mobile, and telephone banking services; and financial education services. The company operates 115 locations and 184 ATMs in metropolitan Chicago, southeast Wisconsin, northwest Indiana, central and western Illinois, eastern Iowa, and other markets in the Midwest. First Midwest Bancorp, Inc. was incorporated in 1982 and is headquartered in Chicago, Illinois.

Full FMBIO Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this FMBIO vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FMBIO vs SCHDFMBIO vs JEPIFMBIO vs OFMBIO vs KOFMBIO vs MAINFMBIO vs ABBVFMBIO vs MRKFMBIO vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.